A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma

Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin wer...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell reports. Medicine Jg. 6; H. 6; S. 102165
Hauptverfasser:	Lopez, Juanita Suzanne, Haefliger, Simon, Plummer, Ruth, Clement, Paul M., Jeffry Evans, Thomas R., Läubli, Heinz, Roth, Patrick, Kristeleit, Rebecca, Brazil, Lucy, Tabatabai, Ghazaleh, Wick, Antje, Wunderlich, Benjamin, Beebe, Kirk, Eisner, Joel Robert, Lane, Heidi, Engelhardt, Marc, Kaindl, Thomas, Hau, Peter, Hundsberger, Thomas, Steinbach, Joachim
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Inc 17.06.2025 Elsevier
Schlagworte:	Administration, Oral Adult Advanced Basic Science Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use astrocytoma Biomarkers, Tumor - metabolism Brain Neoplasms - drug therapy Brain Neoplasms - pathology Dose-Response Relationship, Drug Female glioblastoma Glioblastoma - drug therapy Glioblastoma - metabolism Glioblastoma - pathology glioma Glioma - drug therapy Glioma - metabolism Glioma - pathology Humans lisavanbulin Male Middle Aged Neoplasm Grading glioma glioblastoma lisavanbulin astrocytoma
ISSN:	2666-3791, 2666-3791
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!